FierceBiotech53m
Noema ticks off phase 2a Tourette win for ex-Roche molecule
Noema included other assessments of Tourette symptoms as secondary endpoints. Across the 14 people in the primary analysis, ...
FierceBiotech2h
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
FierceBiotech1h
Kezar rejects Concentra bid that ‘substantially undervalues’ the biotech
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...
FierceBiotech2h
Sage lays off half of R&D team, shakes up C-suite again
Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...
FierceBiotech5h
Sanofi returns to Orano with €300M for radioligand 'pioneer' project
Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...
FierceBiotech19h
Clario and PathAI partner up to create streamlined workflow for gastrointestinal clinical trials
Clinical data company Clario and AI firm PathAI are teaming up to create an end-to-end imaging and pathology workflow for ...